Gilead Says 11% of Prior Non-Responders Cured in Hepatitis Trial
Gilead Sciences Inc. (GILD)’s experimental hepatitis C drug cleared the virus in 11 percent of patients who hadn’t responded to prior treatment, the company said today.
A combination of Gilead’s 7977 drug and the antiviral ribavirin cleared 1 out of 9 so-called “null responder” patients with the most common genotype 1 form of the virus four weeks after ending treatment, the Foster City, California-based company said today in a poster at the European Association for the Study of Liver meeting in Barcelona. The cure rate compares with 88 percent of patients who had never been treated before.
To contact the reporter on this story: Makiko Kitamura in Barcelona via firstname.lastname@example.org
To contact the editor responsible for this story: Reg Gale at email@example.com
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.